论文部分内容阅读
目的:探讨参附注射液与左西孟旦联用治疗急性心力衰竭患者的疗效及其对炎性因子和脑利钠肽(BNP)指标的影响。方法:选取2015年1月—2016年10月间收治的急性心力衰竭患者80例,将其分为对照组和观察组,每组40例;对照组患者给予左西孟旦治疗,观察组患者在对照组基础上加用参附注射液治疗;评价治疗后两组患者的疗效及其对炎性因子和BNP水平的影响。结果:观察组患者治疗后的总有效率高于对照组(P<0.05);两组患者治疗前肿瘤坏死因子-α、超敏C反应蛋白、白介素6等炎症细胞因子和脑利钠肽(BNP)水平经比较其差异无统计学意义(P>0.05),治疗后观察组患者的上述指标均优于对照组(P<0.05)。结论:采用参附注射液与左西孟旦联用治疗急性心力衰竭患者,改善了炎性细胞因子和BNP指标,其疗效优于单用左西孟旦的治疗。
Objective: To investigate the curative effect of Shenfu injection combined with levosimendan in patients with acute heart failure and its effect on inflammatory factors and brain natriuretic peptide (BNP). Methods: Eighty patients with acute heart failure who were admitted between January 2015 and October 2016 were selected and divided into control group and observation group, 40 cases in each group. Patients in the control group were treated with levosimendan. Patients in the observation group On the basis of the control group, Shenfu injection was used to evaluate the curative effect and the effect on the level of inflammatory cytokines and BNP in the two groups after treatment. Results: The total effective rate in observation group was higher than that in control group (P <0.05). The levels of tumor necrosis factor-α, hypersensitive C-reactive protein, interleukin 6 and other inflammatory cytokines and brain natriuretic peptide (P <0.05). After treatment, the above indexes in the observation group were better than those in the control group (P <0.05). Conclusion: Shenfu injection combined with levosimendan in the treatment of acute heart failure patients to improve the inflammatory cytokines and BNP indicators, the effect is superior to the treatment of levosimendan alone.